KOLISTIN-VISTA
Zapytaj lekarza o receptę na KOLISTIN-VISTA
Jak stosować KOLISTIN-VISTA
INSTRUCTIONS for medical use of the medicinal product Olimel N9E
Olimel N9E
Composition:
active substances: alanine; arginine; aspartic acid; glutamic acid; glycine; histidine; isoleucine; leucine; lysine acetate (equivalent to lysine); methionine; phenylalanine; proline; serine; threonine; tryptophan; tyrosine; valine; sodium acetate trihydrate; potassium chloride; magnesium chloride hexahydrate; sodium glycerophosphate, hydrated; glucose, monohydrate (equivalent to anhydrous glucose); calcium chloride, dihydrate; refined olive oil; refined soybean oil.
Pharmaceutical form
Emulsion for infusion.
Main physical and chemical properties
glucose solution with calcium and amino acid solution with electrolytes: clear, colorless or slightly yellow, practically free from particles;
lipid emulsion: homogeneous milky liquid.
Pharmacotherapeutic group
Solutions for parenteral nutrition. Combinations.
ATC code B05B A10.
Pharmacological properties
Pharmacodynamics
The content of nitrogen (L-amino acid series) and calories (glucose and triglycerides) in the Olimel N9E preparation makes it possible to maintain an adequate nitrogen/calorie ratio.
The preparation also contains electrolytes.
Pharmacokinetics
The ingredients of the Olimel N9E preparation (amino acids, electrolytes, glucose, and fats) are distributed, metabolized, and excreted by the same pathways as the individual components.
Clinical characteristics
Indications
For parenteral nutrition of adults and children over 2 years of age when oral or enteral nutrition is impossible, insufficient, or contraindicated.
Contraindications
Age under 2 years.
Hypersensitivity to egg proteins, soy, peanuts, or corn/corn products (see section "Special warnings and precautions for use"), or to any of the active substances or excipients.
Inborn errors of amino acid metabolism.
Expressed hyperlipidemia or severe lipid metabolism disorders characterized by hypertriglyceridemia.
Severe hyperglycemia.
Pathologically elevated plasma concentrations of sodium, potassium, magnesium, calcium, and/or phosphorus.
Interaction with other medicinal products and other forms of interaction
No interaction studies have been conducted.
Olimel N9E should not be administered simultaneously with blood through the same infusion system due to the possibility of pseudoagglutination.
Special warnings and precautions for use
Too rapid administration
Too rapid administration of any complete parenteral nutrition solution may lead to severe or fatal consequences.
Infusion and monitoring
Infusion should be stopped immediately if any symptoms of an allergic reaction appear (such as sweating, increased body temperature, chills, headache, skin rash, or shortness of breath).
Adverse reactions
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
Dosage and administration
Dosage
Olimel N9E is contraindicated for use in children under 2 years of age due to the inappropriate composition and volume (see sections "Pharmacodynamics", "Pharmacokinetics", and "Special warnings and precautions for use").
Children over 2 years of age
No studies have been conducted in pediatric patients.
Overdose
In case of incorrect use (overdose and/or exceeding the recommended infusion rate), signs of hypervolemia and acidosis may appear.
Adverse reactions
Potential undesirable effects may occur as a result of incorrect use (e.g., overdose, too high infusion rate) (see sections "Special warnings and precautions for use" and "Overdose").
Shelf life
2 years.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze. Store in a place inaccessible to children.
Incompatibility
Do not add other medicinal products or substances to any of the chambers of the bag or to the reconstituted emulsion without first ensuring their compatibility and stability of the resulting solution (in particular, the stability of the fat emulsion).
Release category
Prescription only.
Manufacturer
Baxter S.A. / Baxter SA.
Boulevard Rene Branquart 80, Lessines, 7860, Belgium / Boulevard Rene Branquart 80, Lessines, 7860, Belgium.
- Kraj rejestracji
- Substancja czynna
- Wymaga receptyTak
- Producent
- Te informacje mają charakter wyłącznie poglądowy i nie stanowią porady medycznej. Przed zastosowaniem jakiegokolwiek leku zawsze skonsultuj się z lekarzem. Oladoctor nie ponosi odpowiedzialności za decyzje medyczne podjęte na podstawie tych treści.
- Zamienniki KOLISTIN-VISTAPostać farmaceutyczna: powder, 1,000,000 IUSubstancja czynna: colistinWymaga receptyPostać farmaceutyczna: powder, 2000000 IUSubstancja czynna: colistinProducent: АЛТАН ФАРМАСЬЮТІКАЛЗ, С.А.Wymaga receptyPostać farmaceutyczna: powder, 1,000,000 IUSubstancja czynna: colistinWymaga recepty
Odpowiedniki KOLISTIN-VISTA w innych krajach
Najlepsze odpowiedniki z tą samą substancją czynną i działaniem terapeutycznym.
Odpowiednik KOLISTIN-VISTA – Hiszpania
Odpowiednik KOLISTIN-VISTA – Polska
Lekarze online w sprawie KOLISTIN-VISTA
Konsultacja w sprawie dawkowania, działań niepożądanych, interakcji, przeciwwskazań i odnowienia recepty na KOLISTIN-VISTA – decyzja należy do lekarza, zgodnie z lokalnymi przepisami.
Zapisz się na aktualizacje
Otrzymuj informacje o nowych usługach online, zmianach i ofertach dostępnych na Oladoctor w Europie.
